@article{08c32a3f2bff444cb22104ec4d00d4d1,
title = "The clinical course of health status and association with outcomes in patients hospitalized for heart failure: Insights from ASCEND-HF",
abstract = "Aims A longitudinal and comprehensive analysis of health-related quality of life (HRQOL) was performed during hospitalization for heart failure (HF) or soon after discharge. Methods and results A post-hoc analysis was performed of the ASCEND-HF trial. The EuroQOL five dimensions questionnaire (EQ-5D) was administered to study participants at baseline, 24 h, discharge/day 10, and day 30. EQ-5D includes functional dimensions mapped to corresponding utility scores (i.e. 0 = death and 1 = perfect health), and a visual analogue scale (VAS) ranging from 0 (i.e. 'worst imaginable health state') to 100 (i.e. 'best imaginable health state'). The association between baseline and discharge EQ-5D measurements and subsequent clinical outcomes including death and rehospitalization were assessed using multivariable logistic regression and Cox proportional hazards regression. A total of 6943 patients (97%) had complete EQ-5D data at baseline. Mapped utility and VAS scores (mean ± SD) increased over time, respectively, from 0.56 ± 0.23 and 45 ± 22 at baseline to 0.67 ± 0.26 and 58 ± 22 at 24 h and to 0.79 ± 0.20 and 68 ± 22 at discharge, and remained stable at day 30. Lower mapped utility scores at baseline [odds ratio (OR) per 0.1 decrease in utility score 1.03, 95% confidence interval (CI) 1.00-1.06] and discharge (OR 1.10, 95% CI 1.05-1.15) and VAS scores at baseline (OR per 10 point decrease 1.05, 95% CI 1.01-1.09) were significantly associated with increased risk of 30-day all-cause death or HF rehospitalization. Conclusions Patients hospitalized for HF had severely impaired health status at baseline and, although this improved substantially during admission, health status remained abnormal at discharge.",
keywords = "Heart failure, Hospitalization, Morbidity, Mortality, Quality of life",
author = "Ambrosy, {Andrew P.} and Hernandez, {Adrian F.} and Armstrong, {Paul W.} and Javed Butler and Allison Dunning and Ezekowitz, {Justin A.} and Felker, {G. Michael} and Greene, {Stephen J.} and Padma Kaul and McMurray, {John J.} and Marco Metra and O'Connor, {Christopher M.} and Reed, {Shelby D.} and Schulte, {Phillip J.} and Starling, {Randall C.} and {Wilson Tang}, {W. H.} and Voors, {Adriaan A.} and Mentz, {Robert J.}",
note = "Funding Information: Scios Inc. (Mountain View, CA, USA) provided financial and material support for the ASCEND-HF trial. Database management and statistical analysis was performed by the Duke Clinical Research Institute. The authors take responsibility for the manuscript''s integrity, and had complete control and authority over its preparation and the decision to publish. Conflict of interest: A.F.H. reports consulting fees from Sanofi, Johnson and Johnson, AstraZeneca, and Corthera, and research support from Amylin and Scios/Johnson and Johnson. P.W.A. reports research support from Johnson & Johnson. J.B. reports research support from the National Institutes of Health, European Union, and Health Resources Service Administration; and is a consultant to Amgen, Bayer, BG Medicine, Cardiocell, Celladon, Gambro, GE Healthcare, Medtronic, Novartis, Ono Pharma, Takeda, Trevena, and Zensun. J.A.E. reports consulting fees from Pfizer, Abbott Laboratories, and Servier; and research support from Amgen and Johnson and Johnson. G.M.F. reports research funding from Amgen, BG Medicine, Cytokinetics, Johnson & Johnson, Roche Diagnostic Corp, and Otsuka; and consulting fees from Amgen, Cytokinetics, Roche, Otsuka, and Novartis. M.M. has received consulting incomes from Bayer, Novartis, and Servier. M.M.O. reports consulting fees from Novella and Amgen; ownership/partnership/principal in Biscardia, LLC; and research support from Otsuka, Roche Diagnostics, BG Medicine, Critical Diagnostics, Astellas, Gilead, GE Healthcare, and ResMed. R.C.S. reports consulting fees from Novartis, BioControl, and Medtronic; ownership/partnership/principal in Cardiomems; research support from the National Institutes of Health, Medtronic, Biotronik, Novartis, and Thoratec; and receipt of benefits from the American Board of Internal Medicine. W.H.W.T. receives research support from the US National Institutes of Health. A.A.V. has received consultancy fees and/or research grants from Alere, Amgen, Anexon, Bayer, Boehringer Ingelheim, Cardio3Biosciences, Celladon, Merck, Novartis, Servier, Torrent, and Vifor Pharma. R.J.M. receives research support from Amgen, AstraZeneca, BMS, GSK, Gilead, Novartis, Otsuka, and ResMed; and honoraria from Thoratec. All other authors declare no relevant financial disclosures. Publisher Copyright: {\textcopyright} 2015 European Society of Cardiology.",
year = "2016",
month = mar,
day = "1",
doi = "10.1002/ejhf.420",
language = "English (US)",
volume = "18",
pages = "306--313",
journal = "European Journal of Heart Failure",
issn = "1388-9842",
publisher = "Oxford University Press",
number = "3",
}